| Literature DB >> 35056101 |
Soad A Mohamed1, Mohamed A Abdelgawad2, Rania Alaaeldin3, Zeinab Fathalla4, Hossam Moharram5, Raafat M A Abdallah5, Islam M Abdel-Rahman6, Mohamed Abdel-Aziz7, Gamal El-Din A Abuo-Rahma6,7, Mohammed M Ghoneim8, Alaa M Hayallah9,10, Mahmoud Elrehany3, Hamdy Abdelkader1,4,11.
Abstract
Keratitis is a global health issue that claims the eye sight of millions of people every year. Dry eye, contact lens wearing and refractive surgeries are among the most common causes. The resistance rate among fluoroquinolone antibiotics is >30%. This study aims at formulating a newly synthesized ciprofloxacin derivative (2b) niosomes and Solulan C24-, sodium cholate- and deoxycholate-modified niosomes. The prepared niosomal dispersions were characterized macroscopically and microscopically (SEM) and by percentage entrapment efficiency, in vitro release and drug release kinetics. While the inclusion of Solulan C24 produced something discoidal-shaped with a larger diameter, both cholate and deoxycholate were unsuccessful in forming niosomes dispersions. Conventional niosomes and discomes (Solulan C24-modified niosomes) were selected for further investigation. A corneal ulcer model inoculated with colonies of Pseudomonas aeruginosa in rabbits was developed to evaluate the effectiveness of keratitis treatment of the 2b-loaded niosomes and 2b-loaded discomes compared with Ciprocin® (ciprofloxacin) eye drops and control 2b suspension. The histological documentation and assessment of gene expression of the inflammatory markers (IL-6, IL1B, TNFα and NF-κB) indicated that both 2b niosomes and discomes were superior treatments and can be formulated at physiological pH 7.4 compatible with the ocular surface, compared to both 2b suspension and Ciprocin® eye drops.Entities:
Keywords: antibiotic resistance; ciprofloxacin mannich base; corneal ulcer; gene expression; keratitis
Year: 2021 PMID: 35056101 PMCID: PMC8777637 DOI: 10.3390/ph15010044
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247
Figure 1The chemical structure of ciprofloxacin (CIP) and its Mannich base derivative (2b).
Figure 2Photographs of the five different niosomal preparations (the top panel) and size distribution of some selected niosmes (F1) and discomes (F2) (the bottom panel).
Figure 3Scanning electron micrographs for F1 (conventional niosomes) and F2 (discomes) at different magnifications.
Figure 4In vitro release of the ciprofloxacin Mannich derivative (2b) from some selected niosomal formulations and control 2b suspension.
Regression coefficient (R) and release rate constant (K) generated from different kinetics models.
| Formula | Zero | First | Higuchi | Hixon-Crowel | Baker & Lonsdal | Korysmayer-Peppas | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R | K0 | R | K | R | KH | R | KHC | R | K3 | R |
| |
| F1 | 0.79 | 0.72 | −0.79 | −1.6 | 0.999 | 4.3 | 0.79 | 0.72 | 0.98 | 0.0004 | 0.99 | 0.5 |
| F2 | 0.8 | 0.74 | −0.81 | −1.7 | 0.995 | 2.5 | 0.81 | 0.74 | 0.987 | 0.0001 | 0.98 | 0.4 |
| F5 | 0.81 | 0.74 | −0.81 | −1.7 | 0.999 | 2.3 | 0.81 | 0.74 | 0.993 | 0.0001 | 0.98 | 0.44 |
Figure 5Photographic documentation of fluorescein-stained Pseudomonas infected corneal ulcers in rabbit eyes for untreated and treated groups with commercial eye drops, suspension.
Figure 6Histological micrographs of the excised rabbits’ corneas for negative untreated control (a) and untreated positive (infected) control (b,c), hematoxylin and eosin stain × 200 & 400.
Figure 7Histological micrographs of the excised rabbits’ corneas for 2b suspension (A), Ciprocin® eye drops (B), niosomes (C), discomes (D) and hematoxylin and eosin stain × 200 & 400.
Figure 8Expression of IL-6, IL1B, TNFα and NF-κB in normal untreated control (NC) and different groups after treatments. Data presented as means ± SEM. Significant differences were analyzed through one-way ANOVA. Where * p < 0.05; ** p < 0.01; *** p < 0.001, compared to infected untreated group and ## p < 0.01; ### p < 0.001, compared to discomes (F2).
Composition (molar ratio) of various 2b-loaded niosomes.
| Formulation | Drug (%) | Span 60 | Cholesterol | Solulan C24 | Sodium Cholate | Sodium Deoxycholate |
|---|---|---|---|---|---|---|
| F1 | 0.3 | 7 | 3 | - | - | - |
| F2 | 0.3 | 9 | - | 1 | - | - |
| F3 | 0.3 | 9 | - | - | 1 | - |
| F4 | 0.3 | 8 | 1 | - | - | 1 |
| F5 | 0.3 | 8 | 1 | 1 | - | - |
Sequences of the primers generated from NCBI.
| Primer | Sequence of the Primer |
|---|---|
| IL6 | Forward: 5’-GGCACTGGCGGAAGTCAATC-3′ |
| IL-1B | Forward: 5′-AGC TTC TCC AGA GCC ACA AC-3 |
| TNFα | Forward: 5′-GAG AAC CCC ACG GCT AGA TG-3′ |
| NF-κB | Forward: 5′-TGGGGACAGCGTCTTACACC-3′ |
| GAPDH | Forward: 5′-GTC AAG GCT GAG AAC GGG AA-3′ |